当前位置:首页 >财报库 > 报告详情

吉利德科学Gilead Sciences(GILD)2025年第三季度财报(10-Q)「NASDAQ」(英文版)(106页).pdf

上传人: 1****1 编号:999498 2025-12-24 106页 922.35KB

下载:

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549 FORM 10-QQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended September 30,2025orTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934

2、For the transition period from _ to _Commission File No.0-19731 GILEAD SCIENCES,INC.(Exact Name of Registrant as Specified in Its Charter)Delaware94-3047598(State or Other Jurisdiction of Incorporation or Organization)(IRS Employer Identification No.)333 Lakeside Drive,Foster City,California 94404(A

3、ddress of principal executive offices)(Zip Code)650-574-3000(Registrants Telephone Number,Including Area Code)Securities registered pursuant to Section 12(b)of the Act:Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon Stock,par value,$0.001 per shareGILDThe Nasdaq G

4、lobal Select MarketIndicate by check mark whether the registrant:(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934during the preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has been s

5、ubject to such filingrequirements for the past 90 days.Yes x No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T(232.405 of this chapter)during the preceding 12 months(or for such sho

6、rter period that the registrant was required to submit suchfiles).Yes x No Indicate by check mark whether the registrant is a large accelerated filer,an accelerated filer,a non-accelerated filer,a smaller reporting company or anemerging growth company.See the definitions of“large accelerated filer,”

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
根据Gilead Sciences, Inc. 2025年第三季度10-Q表格,以下是关键点: 1. **财务概况**:2025年第三季度,Gilead实现收入76.69亿美元,净利润30.52亿美元,每股摊薄后盈利2.43美元。2025年前9个月,收入215.18亿美元,净利润63.27亿美元。 2. **产品销售**:2025年第三季度,HIV产品销售额为52.77亿美元,肝病产品销售额为8.19亿美元,肿瘤产品销售额为7.88亿美元。 3. **研发投入**:2025年第三季度,研发费用13.46亿美元,其中无形资产减值损失1.9亿美元。 4. **收购与合作**:2025年,Gilead收购了Interius和CymaBay,并与Galapagos、LEO Pharma和Arcus等公司达成合作。 5. **债务情况**:2025年9月30日,Gilead长期债务余额为221.35亿美元。 6. **法律诉讼**:Gilead面临来自多家仿制药公司的专利挑战,并涉及反垄断和消费者保护诉讼。 以上是对Gilead Sciences, Inc. 2025年第三季度10-Q表格的简要概括。
**Gilead营收增长点** **Gilead研发新进展** **Gilead市场风险分析**
客服
商务合作
小程序
服务号
折叠